These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36087070)
1. Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial. Shore ND; Stenzl A; Pieczonka C; Klaassen Z; Aronson WJ; Karsh L; Ryan CJ; Ortiz J; Srinivasan S; Mohamed AF; Verholen F BJU Int; 2023 Apr; 131(4):452-460. PubMed ID: 36087070 [TBL] [Abstract][Full Text] [Related]
2. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095 [TBL] [Abstract][Full Text] [Related]
6. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Kappeler C; Snapir A; Sarapohja T; Smith MR; N Engl J Med; 2019 Mar; 380(13):1235-1246. PubMed ID: 30763142 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial. Fizazi K; Shore ND; Smith M; Ramos R; Jones R; Niegisch G; Vjaters E; Wang Y; Srinivasan S; Sarapohja T; Verholen F Eur J Cancer; 2023 Oct; 192():113258. PubMed ID: 37660438 [TBL] [Abstract][Full Text] [Related]
8. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. Shore ND; Gratzke C; Feyerabend S; Werbrouck P; Carles J; Vjaters E; Tammela TLJ; Morris D; Aragon-Ching JB; Concepcion RS; Emmenegger U; Fleshner N; Grabbert M; Lietuvietis V; Mahammedi H; Cruz FM; Paula A; Pieczonka C; Rannikko A; Richardet M; Silveira G; Kuss I; Le Berre MA; Verholen F; Sarapohja T; Smith MR; Fizazi K Oncologist; 2024 Jul; 29(7):581-588. PubMed ID: 38394384 [TBL] [Abstract][Full Text] [Related]
9. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Petrenciuc O; Snapir A; Sarapohja T; Smith MR; N Engl J Med; 2020 Sep; 383(11):1040-1049. PubMed ID: 32905676 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. Uemura H; Matsushima H; Kobayashi K; Mizusawa H; Nishimatsu H; Fizazi K; Smith M; Shore N; Tammela T; Tabata KI; Matsubara N; Iinuma M; Uemura H; Oya M; Momma T; Kawakita M; Fukasawa S; Kobayashi T; Kuss I; Le Berre MA; Snapir A; Sarapohja T; Suzuki K Int J Clin Oncol; 2021 Mar; 26(3):578-590. PubMed ID: 33226524 [TBL] [Abstract][Full Text] [Related]
11. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison. Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656 [TBL] [Abstract][Full Text] [Related]
12. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Fizazi K; Smith MR; Tombal B Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098 [TBL] [Abstract][Full Text] [Related]
13. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506 [TBL] [Abstract][Full Text] [Related]
14. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial. Fizazi K; Blue I; Nowak JT Future Oncol; 2021 May; 17(14):1699-1707. PubMed ID: 33554636 [TBL] [Abstract][Full Text] [Related]
15. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study. Shore ND; Cruz F; Nordquist L; Belkoff L; Aronson WJ; Tolia B; Cinman A; Sharifi R; Ortiz J; Parkin J; Srinivasan S; Sarapohja T; Smith MR Future Oncol; 2022 Dec; 18(40):4473-4482. PubMed ID: 36753353 [TBL] [Abstract][Full Text] [Related]
17. Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. Scott LJ Target Oncol; 2020 Dec; 15(6):791-799. PubMed ID: 33237495 [TBL] [Abstract][Full Text] [Related]
18. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer]. Zhang F; Lu YP Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306 [TBL] [Abstract][Full Text] [Related]
19. Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. Mori K; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Grossmann NC; Rajwa P; Ploussard G; Briganti A; Kimura T; Egawa S; Papalia R; Carrion DM; Fiori C; Shariat SF; Esperto F; Pradere B Minerva Urol Nephrol; 2022 Jun; 74(3):292-301. PubMed ID: 34308608 [TBL] [Abstract][Full Text] [Related]
20. Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use. Yang CK; Cha TL; Chang YH; Huang SP; Lin JT; Wang SS; Huang CY; Pang ST J Formos Med Assoc; 2023 Apr; 122(4):299-308. PubMed ID: 36797129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]